Consequences of the Poor Anticoagulation Control of Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonists
Journal of Clinical Medicine · 30.10.2024 · 13 (21) · 6495
DOI: 10.3390/jcm13216495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2024. Verfasst von Antoni Sicras Mainar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Atrys Health, 28021 Madrid, Spain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Background
The prevention of thromboembolisms through anticoagulation and heart rate control is crucial in managing non-valvular atrial fibrillation (NVAF). This study aimed to analyze the consequences of poor anticoagulation control with vitamin K antagonists (VKAs) in Spanish patients with NVAF, focusing on thrombotic events, bleeding, mortality, healthcare resources (HRU), and costs.
Methods
This observational, retrospective study used electronic medical records (BIG-PAC® database) of NVAF patients who started VKA treatment between 1 January 2016 and 31 December 2018. Patients were followed up for two years and classified by poor or adequate anticoagulation control. Demographic and clinical characteristics, treatments, incidence of cardiovascular events, mortality rates, HRU, and costs were analyzed.
Results
Patients with poor control (n = 2136) had a 75% greater probability of suffering a cardiovascular event compared to patients with adequate control (n = 2351) (HR, 1.75 [95%CI: 1.43–2.14; p < 0.001]). Cardiovascular events, major bleeding, minor bleeding, systemic thromboembolism, and ischemic strokes were reduced by 32.1%, 46.2%, 29.6%, 22.2%, and 16.1%, respectively. It was estimated that adequate anticoagulant control saved EUR 455/patient with NAVF due to reduced hospitalization for cardiovascular events.
Conclusions
For VKA-treated NVAF patients, poor anticoagulation control was associated with a higher number of cardiovascular events, greater consumption of HRU, and higher management costs than for patients with adequate control.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Atrys Health, 28021 Madrid, Spain.
- Bristol Myers Squibb, 28050 Madrid, Spain.
- Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
- IDIBELL-Instituto de Investigación Biomédica de Bellvitge, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
- CIBERCV-Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Universitat de Barcelona, Hospitalet del Llobregat, 08007 Barcelona, Spain.
ORCID-Profile: Joel Salazar-Mendiguchía, David Vilanova Larena, Josep Comín Colet
Förderung
- Bristol Myers Squibb
Zitieren
APA
Sicras Mainar, A., Salazar-Mendiguchía, J., Del Campo Alonso, M. I., Echeto, A., Vilanova Larena, D., & Comín Colet, J. (2024). Consequences of the Poor Anticoagulation Control of Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonists. Journal of Clinical Medicine, 13(21), 6495. https://doi.org/10.3390/jcm13216495
Vancouver
Sicras Mainar A, Salazar-Mendiguchía J, Del Campo Alonso MI, Echeto A, Vilanova Larena D, Comín Colet J. Consequences of the Poor Anticoagulation Control of Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonists. Journal of Clinical Medicine. 2024;13(21):6495. doi:10.3390/jcm13216495
BibTeX
@article{SicrasMainar2024,
author = {Sicras Mainar, Antoni and Salazar-Mendiguchía, Joel and Del Campo Alonso, María Isabel and Echeto, Ainara and Vilanova Larena, David and Comín Colet, Josep},
title = {Consequences of the Poor Anticoagulation Control of Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonists},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {21},
pages = {6495},
doi = {10.3390/jcm13216495}
}
EUVIMED